The Weight Loss Drug That Outperforms Surgery (And It’s NOT Legal)
The Weight Loss Drug That Outperforms Surgery (And It’s NOT Legal)
There's a new weight loss drug making serious waves in clinical trials. The results are real, science is solid, and people are already using it.
I want to talk about retatrutide, because I've been getting questions about it and because it's already showing up in some wellness clinics without a shred of legal or medical oversight. If you're curious about it, good. You deserve the full picture before anyone talks you into anything.
What Three Receptors Actually Means
"Think of it this way: semaglutide turns down the volume on hunger. Tirzepatide does that and also makes food less rewarding. Retatrutide does both of those things and then throws more wood on the metabolic fire." -- Dr. Kate Dee, Med Spa Confidential podcast
Here's the short version on how these drugs work. Semaglutide (Ozempic, Wegovy) mimics a hormone that tells your brain you're full. Tirzepatide hits two receptors instead of one, which is why weight loss averages around 20 to 22 percent on that drug. Retatrutide hits three.
That third receptor, glucagon, directly increases how fast your body burns energy on top of suppressing appetite. In phase 3 clinical trials, participants lost an average of 28 to 30 percent of their body weight at the highest dose. The average starting weight in one trial was around 248 pounds, and participants lost more than 70 pounds. That's bariatric surgery territory from a once-weekly injection.
The Side Effects Are Not a Small Problem
"For 20 percent of people to experience this strange sensation in their skin, that's something you'd want to know upfront." -- Dr. Kate Dee, Med Spa Confidential podcast
The results are real. So are the side effects. Nausea rates on retatrutide run around 42 to 43 percent at the highest dose, compared to roughly 30 percent on Tirzepatide. Vomiting affects about 25 percent of participants.
And then there's something I hadn't seen before in any GLP-1 drug: dysesthesia. It's an abnormal skin sensation, tingling, burning, prickling, that affected about 21 percent of trial participants. It typically peaks around weeks four to eight and resolves by week 24, but that's one in five people dealing with a genuinely uncomfortable and alarming experience.
The discontinuation rate tells the story clearly. Depending on the trial, up to 18 percent of participants stopped taking the drug because of how they felt. That's nearly one in five people who couldn't finish the course. For a drug that isn't FDA-approved yet, those numbers deserve serious weight.
It's Illegal. Full Stop.
"If someone's offering you Retatrutide today outside of a clinical trial, they're breaking the law. And you're taking on all of that risk with no legal protection, no medical oversight, and no pharmaceutical guarantee on what's in that vial." -- Dr. Kate Dee, Med Spa Confidential podcast
Unlike semaglutide and Tirzepatide, which had a legal compounding window during the shortage period, retatrutide has never been approved. There's no legal pathway for compounders, providers, or patients.
What's circulating in the gray market comes from research-grade suppliers who label it "not for human use" while knowing exactly where it's going. Unknown potency or sterility, no lot numbers and no accountability.
The impressive trial data I just described applies to pharmaceutical-grade Retatrutide manufactured by Eli Lilly under controlled conditions. What a peptide supplier ships you is a different thing entirely.
Before Your Next Appointment
If someone has told you retatrutide is available at their clinic, or if you've been tempted to source it yourself, I hope this gives you a reason to wait. Phase 3 trial results will keep building through 2026, and the FDA filing is expected later this year. If the long-term safety data holds up, we'll have a real, evidence-based conversation about whether it makes sense.
Press play on the full episode of Med Spa Confidential to hear exactly how I break down the risk-benefit math on Retatrutide and what I'd tell a patient who asks me about it today.
